CSL Ltd (CSLLY PINK) stock market data APIs
$79.6456
-0.14(-0.2%)
as of May 23, 2025
Try our APIs with
free plan!
CSL Ltd Financial Data Overview
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
Prev. Close
79.6456
Open
79.506
High
80.7696
Low
78.7342
52 wk Range
70.22-103.2708
Market Cap
77 232 M
P/E Ratio
29.2125
Shares Outstanding
968 M
Revenue
15 230 M
EPS
0.62
Dividends (Yield)
0.0172
Beta
0.334
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get CSL Ltd data using free add-ons & libraries
Get CSL Ltd Fundamental Data
CSL Ltd Fundamental data includes:
- Net Revenue: 15 230 M
- EBITDA: 4 824 M
- Earnings Per Share: 2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-06-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
CSL Ltd News
New
CSL (ASX:CSL) Secures NICE Approval For Sparsentan Use In NHS England
CSL saw its stock price rise by 3% over the last month, amid important developments and a fluctuating market environment. CSL Vifor's notable progress with the National Institute for Health and Care E...
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephropathy, a leading cause of kidney failure 1-3 NICE's recommendation is based on clinically mean...
CSL (ASX:CSL) Hosts Shareholder Information Meeting for Investor Clarity
Following a shareholder information meeting that updated stakeholders on performance and strategy, CSL saw its share price rise by 5% over the past week. Despite the lack of specific earnings or divid...
Australia's CSL evaluates China tariff exemptions for its US-made drugs
By Andrew Silver SHANGHAI (Reuters) -Australia's CSL Ltd said it's evaluating whether its drugs used in surgery would be exempted from 125% tariffs China imposed on U.S.-made goods, as it seeks to mi...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
